Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Indian-origin pharmacy...

    Indian-origin pharmacy technician held guilty of illegally distributing oxycodone pills

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-12-04T09:20:37+05:30  |  Updated On 4 Dec 2019 9:20 AM IST

    Anmol Singh Kamra of Philadelphia, a pharmacy technician conspired with George Fisher, a physician, and Frank Brown, both charged separately, to illegally distribute thousands of oxycodone pills to people suffering from addiction.


    New Delhi: A 27-year-old Indian-origin man has been convicted for conspiring to distribute an opioid pain medication outside the usual course of professional practice and without any legal medical purpose.


    Anmol Singh Kamra of Philadelphia, a pharmacy technician conspired with George Fisher, a physician, and Frank Brown, both charged separately, to illegally distribute thousands of oxycodone pills to people suffering from addiction.


    From about December 2012 through about March 2016, Kamra, Fisher, and Brown carried out a scheme to turn the pharmacy into a pill mill in which Kamra knowingly filled fake oxycodone prescriptions written by Fisher in sham patient names, and gave the oxycodone pills to Brown to sell in street-level drug deals, United States Attorney William McSwain said.


    Also Read: Illegal renting of licences to Chemists: 241 Gujarat Pharmacists lose Registration


    Kamra would sell drugs without a prescription and then ask Fisher to backdate a fake prescription in an attempt to cover the tracks. At trial, Kamra testified that this backdating of prescriptions was a mere "courtesy" on behalf of the doctor so patients could receive their prescriptions in a timely manner, but undercover video evidence showed otherwise.


    The small pharmacy Kamra worked, sold so many opioids that some were hidden under the sink for fear that their distributor would notice the over-abundance and cut them off for exceeding the allowable limit.


    Kamra was operating nothing more than a corrupt pill mill, McSwain said. "The misuse of opioids is killing our citizens, and this defendant significantly contributed to our region's crippling opioid epidemic, adding that everything possible must be done to stop the illegal distribution of these deadly drugs, especially by professionals entrusted to prescribe and monitor their use."


    Also Read: Illegal steroid smuggling ring allegedly led by India-based Alpha Pharma busted in the UK

    Anmol Singh Kamradrug distributionillegalIndianIndian employeeMcSwainopioidopioid epidemicoxycodonepainkillerpharmacypharmacy technicianPhiladelphiaphysicianUS Attorney
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok